Contract award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, Ankyra Therapeutics (“Ankyra”). Ankyra is a Boston-based biotech focused on improving both the safety and efficacy of cancer treatment by using their proprietary anchored immunotherapy platform. Ankyra recently announced a successful US$45 million Series B funding round to finance its lead molecule, ANK-101, through Phase 1 clinical trials and has an emerging pipeline of additional immunotherapy-based programs.  Physiomics will be supporting Ankyra with modelling and simulation of ANK-101 in immune-oncology settings in support of its early development.

Physiomics CEO, Dr Jim Millen, commented: “We are delighted to have been selected by Ankyra Therapeutics as its partner for this modelling and simulation project focused on exciting new molecule ANK-101 and look forward to working with its talented team.”



Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494


Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.